CRC Research Update — October 15, 2026
Today's colorectal cancer research highlights
braf
A collection of 74 issues
KRAS and BRAF mutations drive distinct chromatin and transcriptional programs
Skip to content
The CRC Digest
KRAS and BRAF mutations drive distinct chromatin and transcriptional programs
Isogenic cell models revealed that RAS pathway mutations reconfigure chromatin accessibility and modulate WNT signaling, with elevated TCF7L2 expression in BRAF-mutant tumors independently predicting worse overall survival. (Cell Commun Signal)
This content is informational
CRC Research Update — October 07, 2026
Today's colorectal cancer research highlights
Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer
Skip to content
The CRC Digest
▸ TREATMENT
Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer
A case report describes a 26-year-old woman with microsatellite-stable, BRAF V600E-mutant stage IVC disease who achieved complete remission with first-line immunotherapy and targeted therapy combination, without cytotoxic chemotherapy.
CRC Research Update — October 05, 2026
Today's colorectal cancer research highlights
RTK-RAS pathway alterations show age-dependent clinical significance in colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
RTK-RAS pathway alterations show age-dependent clinical significance in colorectal cancer
RTK-RAS alterations have been associated with unfavorable survival in untreated early-onset non-Hispanic White colorectal cancer, while an opposite association has been observed in FOLFOX-treated late-onset disease. (Journal of Cancer Biology)
This content is
Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer
The REVERCE II trial randomized patients with RAS wild-type metastatic colorectal cancer to receive either regorafenib followed by anti-EGFR therapy or the reverse sequence, evaluating overall survival
CRC Research Update — October 03, 2026
Today's colorectal cancer research highlights
Early-onset CRC shows distinct genomic landscape in dual-cohort analysis
Skip to content
The CRC Digest
◇ RESEARCH
Early-onset CRC shows distinct genomic landscape in dual-cohort analysis
Analysis of TCGA PanCancer Atlas and MSK-IMPACT 50K cohorts reveals reproducible mutational differences in colorectal cancer diagnosed before age 50, with implications for biomarker-driven treatment. (PLoS One)
This content is informational only and does
CRC Research Update — October 01, 2026
Today's colorectal cancer research highlights